New Delhi, April 15 (IANS) Treating patients earlier with a combination of statins and the cholesterol-lowering drug ezetimibe could prevent thousands of new heart attacks, strokes, and death over a decade, according to a new study.
Cardiovascular disease is by far the most common cause of death worldwide, with heart attack (myocardial infarction) being the most common acute event.
For those who survive a heart attack, the risk of a new heart attack is most significant in the first year after the initial event because the blood vessels are more sensitive, making it easier for blood clots to develop.
Reducing LDL or “bad” cholesterol in the blood can stabilise changes in the vessels, decreasing the risk for new events, said researchers from Lund University in Sweden and Imperial College London.
As per current treatment guidelines, patients are prescribed statins immediately after a heart attack. However, most patients do not reach recommended cholesterol levels using only statins, and so need an add-on treatment, such as ezetimibe, the team suggested.
“The study shows that we could save lives and reduce further heart attacks by giving patients a combination of two low-cost drugs. But at the moment patients across the world aren’t receiving these drugs together. That’s causing unnecessary and avoidable heart attacks and deaths — and also places unnecessary costs on healthcare systems,” said co-investigator Professor Kausik Ray, from Imperial College London’s School of Public Health.
“Our study shows the way forward; care pathways must now change for patients after this type of heart event,” he added.
In the study, the international team examined outcomes for heart attacks in 36,000 patients who had a heart attack between 2015 and 2022.
The results show that patients who received a combination treatment of statins and ezetimibe within 12 weeks of a heart attack were able to lower cholesterol to the target level early. They also had a better prognosis and less risk of new cardiovascular events and death than those who received the add-on treatment later, or not at all.
The team said that many new heart attacks, strokes, and deaths could be prevented every year internationally if the treatment strategy were to be changed.
Under a scenario in which 100 per cent of patients would receive ezetimibe early, they estimate 133 heart attacks could be avoided in a population of 10,000 patients in 3 years, they said.
–IANS
rvt/
Disclaimer
The information contained in this website is for general information purposes only. The information is provided by BhaskarLive.in and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website.
Through this website you are able to link to other websites which are not under the control of BhaskarLive.in We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.
Every effort is made to keep the website up and running smoothly. However, BhaskarLive.in takes no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.
For any legal details or query please visit original source link given with news or click on Go to Source.
Our translation service aims to offer the most accurate translation possible and we rarely experience any issues with news post. However, as the translation is carried out by third part tool there is a possibility for error to cause the occasional inaccuracy. We therefore require you to accept this disclaimer before confirming any translation news with us.
If you are not willing to accept this disclaimer then we recommend reading news post in its original language.
